Company intelligence / Profile preview

AIVIS

Seoul, South Koreaaivis.kr ↗

Ownership: Private
Development stage: Commercial

Overview

AIVIS has developed a proprietary AI algorithm capable of quantifying HER2 ultra-low expression and objectively analyzing subtle biomarker patterns in pathology images. Their digital pathology solution is approved by Korea’s Ministry of Food and Drug Safety and is used to support precision diagnostics for breast, thyroid, and colorectal cancers. The company partners with Philips and AstraZeneca to supply its products domestically and internationally.

Therapeutic areas: Oncology
Modalities: DeviceArtificial Intelligence
Industry: Pathology

Drug pipeline

3 assets

PathoAiD-Qanti IHC

Commercial

Indications: Cancer

2 more assets in the full pipeline.

Request access →

Partnerships

PhilipsAstraZeneca

Beyond the preview

Go deeper on AIVIS.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AIVIS.

Explore the full profile